Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest
Ashland to host 2025 Innovation Day for analysts and investors
Ashland Inc. (NYSE: ASH) had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $69.00. They now have an "overweight" rating on the stock.
Ashland Inc. (NYSE: ASH) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $71.00 price target on the stock, up previously from $68.00.
Ashland Wraps Up Divestment of Avoca Business to Mane [Yahoo! Finance]